{
    "id": 33198,
    "fullName": "PIK3CA E722K",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA E722K does not lie within any known functional domains of the Pik3ca protein (UniProt.org). R770Q has been identified in the scientific literature (PMID: 31852484), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "E722K",
    "createDate": "03/30/2020",
    "updateDate": "03/30/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21237,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Elacestrant (RAD1901) treatment resulted in significant tumor growth inhibition in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 5890,
                "therapyName": "Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21236,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) treatment resulted in partial tumor growth inhibition in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21235,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) did not inhibit tumor growth in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21238,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Elacestrant (RAD1901) and Afinitor (everolimus) combination treatment resulted in enhanced tumor growth inhibition compared to single agent treatment in a xenograft (PDX) model of breast cancer harboring PIK3CA E545K and E722K, and ESR1 E380Q that was derived from a patient treated with a combination of Faslodex (fulvestrant) and Ibrance (palbociclib) (PMID: 31852484).",
            "molecularProfile": {
                "id": 35881,
                "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K"
            },
            "therapy": {
                "id": 9643,
                "therapyName": "Elacestrant + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18404,
                    "pubMedId": 31852484,
                    "title": "Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31852484"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35880,
            "profileName": "PIK3CA E722K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35881,
            "profileName": "ESR1 E380Q PIK3CA E545K PIK3CA E722K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}